Delaware Technical Innovation Program

The Wareham Redevelopment Authority has created the Storefront Renovation Grant Program to support improvements to commercial properties and businesses. The program aims to encourage investment within businesses and improve the appearance and safety of major areas within town. The Storefront Renovation Grant program offers grants of up to $7,500 for upgrades such as signage, landscaping, lighting, painting and exterior repairs. Businesses will contribute 20% of project costs.

The city of Mesa has a Business Export Assistance Program that reimburses qualified Mesa-based businesses for up to 50% of expenses related to starting or increasing international exports. To qualify, you need to be headquartered in Mesa and have no more than $25 million in annual sales.

The Small Business Improvement Fund (SBIF) provides reimbursement grant funding for permanent building improvements and repairs across the city. Offered by the Department of Planning and Development (DPD) to tenants and owners of industrial and commercial properties, SBIF grants are funded by Tax Increment Financing (TIF) revenues in designated TIF districts citywide. Program participants can receive grants to cover between 30 percent and 90 percent of the cost of remodeling work, with a maximum grant of $150,000 for commercial properties and $250,000 for industrial properties. The grant, which is administered by SomerCor on the City’s behalf, does not have to be repaid.

Level Up LB is a program designed to propel small businesses towards success and sustainability. This initiative offers entrepreneurs a unique opportunity to connect with essential support resources and undergo comprehensive workshops aimed at crafting new business and marketing plans. Upon completion of the program, participants become eligible to apply for $10,000 grants, empowering them to expand their business capacity and enhance resilience.

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.